(Reuters) – Commissioners at the U.S. Federal Trade Commission (FTC) have not yet met to discuss Amgen’s acquisition of Horizon Therapeutics, CNBC reported on Tuesday.
The news comes a day after reports that the FTC is expected to file a lawsuit as early as Tuesday to block the $27.8 billion deal.
(Reporting by Leroy Leo in Bengaluru; Editing by Arun Koyyur)